Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.46 |
| ▸ | TLR2 | O60603 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620426 | 0.96 | DNM1 (0.48) | DNM1TLR2MEN1KMT2AHTT | |
| SCHEMBL10022753 | 0.89 | DNM1 (0.52) | DNM1TLR2MEN1KMT2AALDH1A1 | |
| SCHEMBL3483124 | 0.87 | HTT (0.48) | DNM1TLR2MEN1KMT2AHTT | |
| SCHEMBL4180677 | 0.84 | DNM1 (0.55) | DNM1TLR2MEN1KMT2AALDH1A1 | |
| SCHEMBL1478563 | 0.83 | HTT (0.52) | DNM1TLR2MEN1KMT2AHTT | |
| SCHEMBL3246465 | 0.83 | DNM1 (0.53) | DNM1TLR2MEN1KMT2AALDH1A1 | |
| SCHEMBL874417 | 0.82 | HTT (0.50) | DNM1TLR2MEN1KMT2AHTT | |
| SCHEMBL29023372 | 0.81 | GRIK1 (0.44) | TLR2 | |
| SCHEMBL26704925 | 0.81 | SPHK1 (0.40) | DNM1MEN1KMT2AHTTTHRB | |
| SCHEMBL16921176 | 0.80 | DNM1 (0.41) | DNM1MEN1KMT2AHTTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130194-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130194-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM1 | DNM1 3350/4885TLR2 4492/4885MEN1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.